Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $61.27, for a total value of $490,160.00. Following the completion of the transaction, the chief financial officer now directly owns 95,679 shares in the company, valued at approximately $5,862,252.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $69.02, for a total transaction of $552,160.00.

Vaxcyte Trading Down 1.0 %

NASDAQ PCVX opened at $60.30 on Thursday. Vaxcyte, Inc. has a 1-year low of $41.57 and a 1-year high of $82.04. The company has a market capitalization of $6.56 billion, a PE ratio of -14.60 and a beta of 0.89. The firm’s fifty day simple moving average is $68.55 and its 200-day simple moving average is $61.28.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period last year, the business earned ($0.73) EPS. As a group, analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on PCVX shares. Bank of America boosted their target price on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Needham & Company LLC reissued a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research note on Wednesday, April 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $78.50.

Hedge Funds Weigh In On Vaxcyte

Hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its stake in shares of Vaxcyte by 1,005.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company’s stock worth $1,419,000 after acquiring an additional 20,558 shares during the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of Vaxcyte in the fourth quarter worth $3,035,000. Wellington Management Group LLP increased its stake in shares of Vaxcyte by 3.8% in the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after acquiring an additional 167,501 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Vaxcyte by 20.6% in the third quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after acquiring an additional 300,189 shares during the last quarter. Finally, UBS Group AG boosted its holdings in Vaxcyte by 62.2% in the third quarter. UBS Group AG now owns 74,305 shares of the company’s stock worth $3,788,000 after purchasing an additional 28,483 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.